Page 115 - CIBERER2016-ENG

Most relevant scientific articles
• Mojica F.J.M., Montoliu L. On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals. Trends in Microbiology. 2016;24(10):811-820.
• Lopez-Luque J., Caballero-Diaz D., Martinez-Palacian A., Roncero C., Moreno-Caceres J., Garcia- Bravo M. et al. Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis. Hepatology. 2016;63(2):604-619.
• Oliveros JC, Franch M, Tabas-Madrid D, San-León D, Montoliu L, Cubas P et al. Breaking-Cas- interactive design of guide RNAs for CRISPR-Cas experiments for ENSEMBL genomes.Nucleic acids research. 2016;44(W1): W267-71.
Hightlights
During 2016, our group has consolidated the CRISPR technology, which we have applied for the generation of several new mouse models that were previously validated in cells. In particular, we have generated
new genome-edited mouse models for oculocutaneous albinism type 1 (OCA1), type 2 (OCA2) and other types of albinism, from the list of 20 genes whose mutations are associated with some type of albinism. In addition, we have contributed to develop a new free web tool for the optimized design of RNA guides to
be used with CRISPR systems. This new bioinformatic tool, Breaking-Cas, allows the use of any sequenced genome, as long as it has been deposited and is available through the Ensembl public platform. The web tool allows, also, to select a wide variety of Cas and Cas-like proteins, as well as experimental conditions important to restrict the selection of guide RNAs. The Breaking-Cas tool has been used for the successful design of the entire list of new mouse models generated recently in the laboratory. With regard with our activities of genetic diagnose of albinism, through the strategy we devised called ALBINOCHIP, developed in collaboration with Angel Carracedo’s unit, in Santiago de Compostela, we have progressed and obtained results from patients and their relatives. Regarding our activities with patient associations we should highlight the third European Days of Albinism (3EDA), held in Milano on 7-8 April, where we met with other international experts and many other European associations in support of people with albinism. Finally, with the support from ALBA and CIBERER, we have collaborated in the making of a video project, entitled “See this?”, directed by Patty Bonet, whose aim is to show the world, using subjective vision, how a person with albinism can see. With ALBA we celebrated 10 years of the association in Valencia.
ER
research groups 115